Bicalutamide in Treating Patients With Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

March 23, 2007

Primary Completion Date

June 24, 2021

Study Completion Date

June 24, 2021

Conditions
Breast Cancer
Interventions
DRUG

bicalutamide

OTHER

diagnostic laboratory biomarker analysis

OTHER

immunohistochemistry staining method

Trial Locations (8)

10035

Ralph Lauren Center for Cancer Care and Prevention, New York

10065

Memorial Sloan Kettering Cancer Center, New York

20007

Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington D.C.

27710

Duke Cancer Institute, Durham

55905

Mayo Clinic Cancer Center, Rochester

94115

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

02115

Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute, Boston

27599-7295

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

AstraZeneca

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER